TIM-3 as a new therapeutic target in systemic lupus erythematosus
- 19 September 2009
- journal article
- review article
- Published by Springer Nature in Molecular Biology Reports
- Vol. 37 (1) , 395-398
Abstract
T-cell immunoglobulin- and mucin-domain-containing molecule-3 (TIM-3) was the first surface molecule that specifically identifies Th1 cells in both mice and human. Recently, identification of Galectin-9 as a ligand for TIM-3 has established the TIM-3–Galectin-9 pathway as an important regulator of Th1 immunity and tolerance induction. Many previous studies have demonstrated that TIM-3 influences chronic autoimmune diseases, such as multiple sclerosis and rheumatoid arthritis. In addition, association of TIM-3 polymorphisms with susceptibility to several autoimmune diseases has been identified. Recent work has explored the role of TIM-3 in systemic lupus erythematosus (SLE), and their results indicate that TIM-3 may represent a novel target for the treatment of SLE. In this review, we will discuss the TIM-3 pathway and the therapeutic potential of modulating the pathway in SLE.Keywords
This publication has 25 references indexed in Scilit:
- Stable form of galectin-9, a Tim-3 ligand, inhibits contact hypersensitivity and psoriatic reactions: A potent therapeutic tool for Th1- and/or Th17-mediated skin inflammationClinical Immunology, 2009
- The costimulatory role of TIM moleculesImmunological Reviews, 2009
- Tim-3 mediates phagocytosis of apoptotic cells and cross-presentationBlood, 2009
- Blockade of Tim-3 Pathway Ameliorates Interferon-γ Production from Hepatic CD8+ T Cells in a Mouse Model of Hepatitis B Virus InfectionCellular & Molecular Immunology, 2009
- TIM-1 and TIM-3 proteins in immune regulationCytokine, 2008
- Dysregulated T cell expression of TIM3 in multiple sclerosisJournal of Experimental Medicine, 2006
- The polymorphisms of Th1 cell surface gene Tim-3 are associated in a Korean population with rheumatoid arthritisImmunology Letters, 2004
- Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune diseaseNature, 2002
- Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice.Journal of Clinical Investigation, 1998
- Experimental therapy of systemic lupus erythematosus: the treatment of NZB/W mice with mouse soluble interferon‐γ receptor inhibits the onset of glomerulonephritisEuropean Journal of Immunology, 1995